Brief: Immix Biopharma Announces 16th Patient Dosing In Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial
20/12/2022 13:03
Dec 20 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES 16TH PATIENT DOSING IN ONGOING
PHASE
1B/2A IMX-110 MONOTHERAPY CLINICAL TRIAL
Source text for Eikon: ID:nGNX5WmWgL
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary